
Cerus Corporation CERS
$ 2.61
0.38%
Cerus Corporation Cost of Revenue | CERS
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Cerus Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 33.4 M | 31.6 M | 22.5 M | 20.3 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 33.4 M | 20.3 M | 27 M |
Quarterly Cost of Revenue Cerus Corporation
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 17.6 M | 15.3 M | 11.1 M | - | 11 M | 9.7 M | 8.32 M | - | 7.58 M | 8.11 M | 8.43 M | - | 8.14 M | 7.72 M | 7.33 M | - | 5.35 M | 4.36 M | - | - | - | - | - | - | 5.56 M | - | - | - | 5.69 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 17.6 M | 4.36 M | 8.83 M |
Cost of Revenue of other stocks in the Biotechnology industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
BioLineRx Ltd.
BLRX
|
230 K | $ 2.52 | 1.17 % | $ 6.21 B | ||
|
BioMarin Pharmaceutical
BMRN
|
717 M | $ 61.35 | 0.06 % | $ 11.8 B | ||
|
BioNTech SE
BNTX
|
642 M | $ 99.26 | 0.81 % | $ 24 B | ||
|
Burford Capital Limited
BUR
|
43.6 M | $ 3.63 | 3.93 % | $ 795 M | ||
|
Amryt Pharma plc
AMYT
|
106 M | - | - | $ 621 M | ||
|
Catalyst Biosciences
CBIO
|
5.42 M | $ 14.24 | 0.35 % | $ 1.27 B | ||
|
Codexis
CDXS
|
9.34 M | $ 1.37 | 1.45 % | $ 119 M | ||
|
AbbVie
ABBV
|
18.2 B | $ 265.12 | 0.09 % | $ 469 B | ||
|
Coherus BioSciences
CHRS
|
13.8 M | $ 1.17 | 1.48 % | $ 137 M | ||
|
Abeona Therapeutics
ABEO
|
1.53 M | $ 5.43 | 2.65 % | $ 288 M | ||
|
Celldex Therapeutics
CLDX
|
200 K | $ 31.48 | 1.16 % | $ 2.09 B | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
835 K | $ 4.12 | 1.98 % | $ 50.3 M | ||
|
Cocrystal Pharma
COCP
|
406 K | $ 1.15 | 1.67 % | $ 13 M | ||
|
Crinetics Pharmaceuticals
CRNX
|
1.08 M | $ 84.95 | 0.13 % | $ 7.99 B | ||
|
Collegium Pharmaceutical
COLL
|
77.1 M | $ 22.64 | 0.85 % | $ 717 M | ||
|
Corcept Therapeutics Incorporated
CORT
|
13 M | $ 118.51 | 4.93 % | $ 12.3 B | ||
|
Chimerix
CMRX
|
447 K | - | - | $ 756 M | ||
|
CorMedix
CRMD
|
22.1 M | $ 7.77 | 1.04 % | $ 560 K | ||
|
Champions Oncology
CSBR
|
30.9 M | $ 4.95 | 0.38 % | $ 68.5 M |